Philip Hoffman to Salvage Therapy
This is a "connection" page, showing publications Philip Hoffman has written about Salvage Therapy.
Connection Strength
0.167
-
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 10; 14(10):1847-1852.
Score: 0.145
-
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8.
Score: 0.022